Gunnar Heine
@gunnarheine.bsky.social
Internist Saarland University Homburg
Nephrologist AGAPLESION MARKUS KRANKENHAUS Frankfurt
Editor MARKUS at HOMe
YouTube Editor NDT
Nephrologist AGAPLESION MARKUS KRANKENHAUS Frankfurt
Editor MARKUS at HOMe
YouTube Editor NDT
Reposted by Gunnar Heine
Reposted by Gunnar Heine
Last days of summer...
September 7, 2025 at 7:28 PM
Last days of summer...
Reposted by Gunnar Heine
Tonight it's all about ADPKD!
KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller
youtu.be/qjnYDsYbx0Q?...
@rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social
KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller
youtu.be/qjnYDsYbx0Q?...
@rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social
ADPKD: KDIGO GL / ERA Genes & Kidney WG - Prof. Roser Torra, Prof. Roman-Ulrich Müller
YouTube video by MARKUS at HOMe
youtu.be
September 12, 2025 at 5:54 PM
Tonight it's all about ADPKD!
KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller
youtu.be/qjnYDsYbx0Q?...
@rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social
KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller
youtu.be/qjnYDsYbx0Q?...
@rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social
Reposted by Gunnar Heine
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
October 14, 2025 at 7:48 PM
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
Reposted by Gunnar Heine
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al.
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
October 16, 2025 at 6:48 PM
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al.
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
Reposted by Gunnar Heine
Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK)
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
Novel developments in the treatment of HFREF - Prof. Dr. John McMurray (Glasgow, UK)
YouTube video by MARKUS at HOMe
youtu.be
October 17, 2025 at 6:02 PM
Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK)
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
Reposted by Gunnar Heine
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
October 23, 2025 at 5:47 PM
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
Reposted by Gunnar Heine
Our experts explain:
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. Cornec-Le Gall, Prof. Halbritter, Prof. Müller
YouTube video by MARKUS at HOMe
youtu.be
October 24, 2025 at 6:35 PM
Our experts explain:
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
Reposted by Gunnar Heine
Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
October 28, 2025 at 7:50 PM
Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
Reposted by Gunnar Heine
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
YouTube video by MARKUS at HOMe
youtu.be
October 31, 2025 at 6:21 PM
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
Reposted by Gunnar Heine
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
October 30, 2025 at 8:58 PM
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
Reposted by Gunnar Heine
New DGfN Board elected!
Prof. Julia Weinmann-Menke joins the board of the German Society of Nephrology.
Prof. Martin K. Kuhlmann (President), Prof. Elke Schäffner and PD Dr. Georg Schlieper were re-elected.
More info 👉 www.dgfn.eu/vorstand.html
#Nephrology #DGfN #CKD
Prof. Julia Weinmann-Menke joins the board of the German Society of Nephrology.
Prof. Martin K. Kuhlmann (President), Prof. Elke Schäffner and PD Dr. Georg Schlieper were re-elected.
More info 👉 www.dgfn.eu/vorstand.html
#Nephrology #DGfN #CKD
October 14, 2025 at 12:24 PM
New DGfN Board elected!
Prof. Julia Weinmann-Menke joins the board of the German Society of Nephrology.
Prof. Martin K. Kuhlmann (President), Prof. Elke Schäffner and PD Dr. Georg Schlieper were re-elected.
More info 👉 www.dgfn.eu/vorstand.html
#Nephrology #DGfN #CKD
Prof. Julia Weinmann-Menke joins the board of the German Society of Nephrology.
Prof. Martin K. Kuhlmann (President), Prof. Elke Schäffner and PD Dr. Georg Schlieper were re-elected.
More info 👉 www.dgfn.eu/vorstand.html
#Nephrology #DGfN #CKD
Reposted by Gunnar Heine
How to diagnose and treat superficial vein thrombosis (SuVT) by Drs. Piazza, Bikdeli et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
September 16, 2025 at 6:47 PM
How to diagnose and treat superficial vein thrombosis (SuVT) by Drs. Piazza, Bikdeli et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Gunnar Heine
KDIGO publishes its new guidelines on IgA Nephropathy (IgAN) / IgA Vasculitis (IgAV)
kdigo.org/guidelines/i...
kdigo.org/guidelines/i...
September 18, 2025 at 7:58 PM
KDIGO publishes its new guidelines on IgA Nephropathy (IgAN) / IgA Vasculitis (IgAV)
kdigo.org/guidelines/i...
kdigo.org/guidelines/i...
Reposted by Gunnar Heine
Primäre Hyperoxalurie - Prof. Dr. Bernd Hoppe (Bonn)
Prof. Dr. Bernd Hoppe explains the pathophysiology, diagnostics, current and possible future therapies of primary hyperoxaluria.
youtu.be/T18mxSSlG7g?...
Prof. Dr. Bernd Hoppe explains the pathophysiology, diagnostics, current and possible future therapies of primary hyperoxaluria.
youtu.be/T18mxSSlG7g?...
Primäre Hyperoxalurie - Prof. Dr. Bernd Hoppe (Bonn)
YouTube video by MARKUS at HOMe
youtu.be
September 19, 2025 at 6:51 PM
Primäre Hyperoxalurie - Prof. Dr. Bernd Hoppe (Bonn)
Prof. Dr. Bernd Hoppe explains the pathophysiology, diagnostics, current and possible future therapies of primary hyperoxaluria.
youtu.be/T18mxSSlG7g?...
Prof. Dr. Bernd Hoppe explains the pathophysiology, diagnostics, current and possible future therapies of primary hyperoxaluria.
youtu.be/T18mxSSlG7g?...
Reposted by Gunnar Heine
Anti-glomerular Basement Membrane Disease - Treatment Standard by Drs. McAdoo, Pusey et al.
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...
September 24, 2025 at 5:59 PM
Anti-glomerular Basement Membrane Disease - Treatment Standard by Drs. McAdoo, Pusey et al.
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...
Reposted by Gunnar Heine
Atypical Hemotytic Uremic Syndrome (aHUS) - Prof. Fadi Fakhouri (Lausanne, Switzerland)
youtu.be/k0UlfUh_PZU?...
Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).
youtu.be/k0UlfUh_PZU?...
Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).
Atypical Hemotytic Uremic Syndrome (aHUS) - Prof. Fadi Fakhouri (Lausanne, Switzerland)
YouTube video by MARKUS at HOMe
youtu.be
September 26, 2025 at 5:10 PM
Atypical Hemotytic Uremic Syndrome (aHUS) - Prof. Fadi Fakhouri (Lausanne, Switzerland)
youtu.be/k0UlfUh_PZU?...
Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).
youtu.be/k0UlfUh_PZU?...
Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).
Reposted by Gunnar Heine
Abnormal electrocardiogram findings in athletes by Drs. Finocchiaro, D’Ascenzi et al.
A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology!
academic.oup.com/eurheartj/ar...
A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology!
academic.oup.com/eurheartj/ar...
October 1, 2025 at 7:43 PM
Abnormal electrocardiogram findings in athletes by Drs. Finocchiaro, D’Ascenzi et al.
A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology!
academic.oup.com/eurheartj/ar...
A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology!
academic.oup.com/eurheartj/ar...
Reposted by Gunnar Heine
Impfungen 25 / 26: Influenza, SARS-CoV-2, RSV, Pneumokokken - Prof. Dr. Klaus Stöhr, Prof. Dr. Barbara Gärtner
youtu.be/V5P-eDvf9jI?...
youtu.be/V5P-eDvf9jI?...
Impfungen 25 / 26: Influenza, SARS-CoV-2, RSV - Prof. Dr. Klaus Stöhr, Prof. Dr. Barbara Gärtner
YouTube video by MARKUS at HOMe
youtu.be
October 5, 2025 at 6:20 PM
Impfungen 25 / 26: Influenza, SARS-CoV-2, RSV, Pneumokokken - Prof. Dr. Klaus Stöhr, Prof. Dr. Barbara Gärtner
youtu.be/V5P-eDvf9jI?...
youtu.be/V5P-eDvf9jI?...
Reposted by Gunnar Heine
Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. Fontana, Gillmore et al.
academic.oup.com/eurheartj/ar...
academic.oup.com/eurheartj/ar...
October 7, 2025 at 6:58 PM
Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. Fontana, Gillmore et al.
academic.oup.com/eurheartj/ar...
academic.oup.com/eurheartj/ar...
Reposted by Gunnar Heine
The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
October 9, 2025 at 6:49 PM
The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
Reposted by Gunnar Heine
SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
SGLT-2 I in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
YouTube video by MARKUS at HOMe
youtu.be
October 10, 2025 at 6:21 PM
SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
Reposted by Gunnar Heine
Where the sea meets the sky, peace begins
August 17, 2025 at 7:23 PM
Where the sea meets the sky, peace begins
Reposted by Gunnar Heine
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
YouTube video by MARKUS at HOMe
youtu.be
August 15, 2025 at 4:50 PM
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
youtu.be/RXttWKQ-sM4?...
Prof Mahé and Prof. Couturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
Reposted by Gunnar Heine
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline by Drs. McIntyre, Taljaard et al.
www.nejm.org/doi/full/10....
Lactated Ringer’s solution rather than normal saline did not result in a lower incidence of death or readmission to the hospital.
www.nejm.org/doi/full/10....
Lactated Ringer’s solution rather than normal saline did not result in a lower incidence of death or readmission to the hospital.
August 14, 2025 at 5:27 PM
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline by Drs. McIntyre, Taljaard et al.
www.nejm.org/doi/full/10....
Lactated Ringer’s solution rather than normal saline did not result in a lower incidence of death or readmission to the hospital.
www.nejm.org/doi/full/10....
Lactated Ringer’s solution rather than normal saline did not result in a lower incidence of death or readmission to the hospital.